In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Genmab A/S

Everything’s Coming Up Pfizer: The Biggest Of Pharma Firms Leads Industry In Pending Applications For US FDA Approval

Pfizer’s lineup of novel agents under review stands at seven, while no other big pharma has more than two novel candidates; Sanofi is tops in recent approvals since 2021, with seven novel agents cleared, but has no pending NMEs.

US FDA Performance Tracker Drug Review

Genmab Geared Up To Launch Epkinly With AbbVie

The Danish group, along with partner AbbVie, is all set for a commercial battle with Roche as Epkinly hits the US market for refractory diffuse large B-cell lymphoma a few weeks ahead of expected approval for the Swiss major’s same-in-class rival glofitamab.

Approvals Cancer

Keeping Track: Genmab/AbbVie Epkinly, Krystal’s Vyjuvek Join US FDA’s 2023 Novel Approvals List

Oncology's surprisingly low numbers this year are among the latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

US FDA Performance Tracker Approvals

Janssen Gives Next-Gen CAR-Ts Another Shot After Fate Deal’s Collapse

A new collaboration with Cellular Biomedicine includes a CD19/CD20-directed bispecific CAR-T in Phase I development for B-cell non-Hodgkin lymphomas.

Deals ImmunoOncology
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
UsernamePublicRestriction

Register